Effects of <scp>GLP</scp>‐1 Receptor Agonists on Paediatric Population in a Real World Setting
Paediatric patients with T2DM using GLP-1 receptor agonists experienced a significant decrease in HbA1c after 12 months of use, which was not sustained at 24 months. However, patients had a reduction in insulin and metformin use at 12 months. No significant impact was appreciated on BMI or other metabolic variables.
Authors
- Antonio Barajas‐Martínez (ORCID: https://orcid.org/0000-0002-5299-0259)
- Jessica Schmitt (ORCID: https://orcid.org/0000-0003-0733-2000)
- Charles A. Gagnon‐Vargas
Institutions
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Endocrinology Diabetes & Metabolism
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1002/edm2.70053
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences